DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Investment Public disclosure of inside information in accordance with the amended version of Article 17(1) of Regulation (EU) No 596/2014 on market abuse (Market Abuse Regulation, "MAR") Dermapharm Holding SE acquires equity investment in CORAT Therapeutics GmbH Grünwald, 7 July 2021 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) today, via Dermapharm AG, entered into an agreement to acquire an equity investment and new shares in CORAT Therapeutics GmbH, Braunschweig, Germany. Upon the completion of the capital increase, Dermapharm AG acquires 24.9% of the shares in the company, which is developing an antibody drug for treating COVID-19. The drug, which would be used to treat hospitalised patients with moderate to severe symptoms of COVID-19, is currently undergoing testing in a clinical phase Ib/II trial. It has been shown to reduce the viral load (SARS-CoV-2) in the lungs by 99.4%. The parties have agreed to keep the purchase price for the shares confidential. >End of ad hoc disclosure<
Contact Investor Relations & Corporate Communications
07-Jul-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Dermapharm Holding SE |
Lil-Dagover-Ring 7 | |
82031 Grünwald | |
Germany | |
Phone: | +49 (0)89 64 86-0 |
E-mail: | ir@dermapharm.com |
Internet: | ir.dermapharm.de |
ISIN: | DE000A2GS5D8 |
WKN: | A2GS5D |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange |
EQS News ID: | 1216404 |
End of Announcement | DGAP News Service |
|
1216404 07-Jul-2021 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.